Intentional Intrathecal Opioid Detoxification in 3 Patients: Characterization of the Intrathecal Opioid Withdrawal Syndrome

Pain Practice

Volumn 13, Issue 4, 2013, Pages 297-309

  Jackson, Tracy P ^a   Lonergan, Daniel F ^a   Todd, R David ^a   Martin, Peter R ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Detoxification; Implantable; Infusion pumps; Opioids

Indexed keywords

AMITRIPTYLINE; BUPIVACAINE; BUPRENORPHINE; CLONIDINE; GABAPENTIN; HYDROMORPHONE; MAGNESIUM; MELOXICAM; METHADONE; MORPHINE; OPIATE; PARACETAMOL;

ADULT; AGED; AGITATION; ANALGESIA; ANHEDONIA; APPETITE DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; CASE REPORT; CLAUDICATION; CLINICAL ASSESSMENT TOOL; CLINICAL OPIATE WITHDRAWAL SCALE; DAILY LIFE ACTIVITY; DEPRESSION; DETOXIFICATION; DIARRHEA; DISEASE SEVERITY; DIURESIS; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; DYSPHORIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EVENING DOSAGE; EXERCISE; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; HYPERALGESIA; HYPERTENSION; KINESIOTHERAPY; LACRIMATION DISORDER; LAMINECTOMY; LEG EDEMA; LEG PAIN; LOW BACK PAIN; MALE; NAUSEA; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; QUALITY OF LIFE; RESTLESSNESS; SEDATION; SEXUAL DYSFUNCTION; SNEEZING; SOMNOLENCE; TACHYCARDIA; TASTE AVERSION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME; YAWNING;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; CLONIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SPINAL; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84875962041     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2012.00584.x     Document Type: Article

References (91)

1. Fields HL. Should we be reluctant to prescribe opioids for chronic non-malignant pain?Pain. 2007;129:233-234.
2. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-R1051.
3. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21:1555-1568.
4. Clark AJ, Lynch ME. Therapy of chronic non-malignant pain with opioids. Can J Anaesth. 2003;50:92; author reply 92.
5. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008;11:S181-S200.
6. Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician. 2009;12:345-360.
7. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011;14:219-248.
8. Koulousakis A, Kuchta J, Bayarassou A, Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl. 2007;97:43-48.
9. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain. 2004;109:242-249.
10. Miles J. Intrathecal therapy for chronic pain. Stereotact Funct Neurosurg. 2001;77:156-158.
11. Coffey RJ, Owens ML, Broste SK, et al.Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111:881-891.
12. Grider JS, Harned ME, Sloan PA. Patient selection and trialing techniques utilizing low-dose intrathecal morphine for chronic nonmalignant pain: a report of two cases. J Opioid Manag. 2010;6:371-376.
13. Grider JS, Harned ME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Physician. 2011;14:343-351.
14. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357-366.
15. Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5:353-361.
16. Kittelberger KP, Buchheit TE, Rice SF. Self-extraction of intrathecal pump opioid. Anesthesiology. 2004;101:807.
17. Williams BS, Wong D, Amin S. Case scenario: self-extraction of intrathecal pump medication with a concomitant intrathecal granulomatous mass. Anesthesiology. 2011;114:424-430.
18. Chu LF, Dairmont J, Zamora AK, Young CA, Angst MS. The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain. 2011;12:108-115.
19. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479-496.
20. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570-587.
21. Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9:724-727.
22. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994;59:313-316.
23. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006;2:277-282.
24. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4:123-130.
25. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005;80:319-324.
26. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679-684.
27. Singla A, Stojanovic MP, Chen L, Mao J. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg. 2007;105:1816-1819, table of contents.
28. Cabbell KL, Taren JA, Sagher O. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery. 1998;42:1176-1180; discussion 1180-1171.
29. Hu K, Connelly NR, Vieira P. Withdrawal symptoms in a patient receiving intrathecal morphine via an infusion pump. J Clin Anesth. 2002;14:595-597.
30. Tung AS, Tenicela R, Winter PM. Opiate withdrawal syndrome following intrathecal administration of morphine. Anesthesiology. 1980;53:340.
31. Knight KH, Brand FM, McHaourab AS, Veneziano G. Implantable intrathecal pumps for chronic pain: highlights and updates. Croat Med J. 2007;48:22-34.
32. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35:253-259.
33. Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. 1978;2:599-602.
34. Martin PR, Patel S, Swift RM. Pharmacology of Drugs of Abuse. In: Golan DE, ed. The Pathophysiologic Basis of Drug Therapy. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 2011: 284-309.
35. Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978;276:186-188.
36. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry. 1985;42:1063-1066.
37. Fingerhood MI, Thompson MR, Jasinski DR. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst Abus. 2001;22:193-199.
38. Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009;CD002024.
39. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009;CD002025.
40. Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90:261-269.
41. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000;61:85-94.
42. Jacobs EA, Bickel WK. Precipitated withdrawal in an opioid-dependent outpatient receiving alternate-day buprenorphine dosing. Addiction. 1999;94:140-141.
43. Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17:715-718.
44. Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al.The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009;25:1517-1528.
45. Mercadante S, Porzio G, Fulfaro F, et al.Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage. 2007;34:532-538.
46. Devulder J, Bohyn P, Castille F, De Laat M, Rolly G. A case of uncommon withdrawal symptoms after a short period of spinal morphine administration. Pain. 1996;64:589-591.
47. Raffaelli W, Salmosky-Dekel BG. Biological consequences of long-term intrathecal administration of opioids. Minerva Anestesiol. 2005;71:475-478.
48. Cridland RA, Sutak M, Jhamandas K. Characteristics of precipitated withdrawal from spinal morphine: changes in [Met5]enkephalin levels. Eur J Pharmacol. 1991;203:93-103.
49. Gardell LR, King T, Ossipov MH, et al.Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006;396:44-49.
50. Gardell LR, Wang R, Burgess SE, et al.Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002;22:6747-6755.
51. Ossipov MH, Lai J, Malan TP Jr, Porreca F. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci. 2000;909:12-24.
52. Ossipov MH, Lai J, Vanderah TW, Porreca F. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci. 2003;73:783-800.
53. Xie JY, Herman DS, Stiller CO, et al.Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 2005;25:409-416.
54. Zhang W, Gardell S, Zhang D, et al.Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain. 2009;132:778-787.
55. Eisenach JC, Hood DD, Curry R. Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg. 1998;87:591-596.
56. Hayashida KI, Bynum T, Vincler M, Eisenach JC. Inhibitory M2 muscarinic receptors are upregulated in both axotomized and intact small diameter dorsal root ganglion cells after peripheral nerve injury. Neuroscience. 2006;140:259-268.
57. Milne B, Cervenko FW, Jhamandas K, Sutak M. Intrathecal clonidine: analgesia and effect on opiate withdrawal in the rat. Anesthesiology. 1985;62:34-38.
58. Martin PR, Ebert MH, Gordon EK, Linnoila M, Kopin IJ. Effects of clonidine on central and peripheral catecholamine metabolism. Clin Pharmacol Ther. 1984;35:322-327.
59. Wala EP, Holtman JR Jr. Buprenorphine-induced hyperalgesia in the rat. Eur J Pharmacol. 2011;651:89-95.
60. Pergolizzi J, Aloisi AM, Dahan A, et al.Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428-450.
61. Koppert W, Ihmsen H, Korber N, et al.Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118:15-22.
62. Fine PG. Opioid insights: opioid-induced hyperalgesia and opioid rotation. J Pain Palliat Care Pharmacother. 2004;18:75-79.
63. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med. 2009;10:829-839.
64. Marshall DC, Buccafusco JJ. Supraspinal and spinal mediation of naloxone-induced morphine withdrawal in rats. Brain Res. 1985;329:131-142.
65. Buccafusco JJ. Participation of different brain regions in the anti-narcotic withdrawal action of clonidine in the dependent rat. Brain Res. 1990;513:8-14.
66. Marshall DC, Buccafusco JJ. Spontaneous morphine withdrawal from the rat spinal cord. Experientia. 1985;41:1151-1152.
67. Marshall DC, Buccafusco JJ. Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. J Neurosci. 1987;7:621-628.
68. Hayashida K, Eisenach JC. Multiplicative interactions to enhance gabapentin to treat neuropathic pain. Eur J Pharmacol. 2008;598:21-26.
69. Naguib M, Yaksh TL. Antinociceptive effects of spinal cholinesterase inhibition and isobolographic analysis of the interaction with mu and alpha 2 receptor systems. Anesthesiology. 1994;80:1338-1348.
70. Takasu K, Honda M, Ono H, Tanabe M. Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury. Br J Pharmacol. 2006;148:233-244.
71. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287-297.
72. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999;44:289-300; discussion 300-281.
73. Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain. 2000;4:361-365.
74. Ruan X, Liu H, Couch JP, Wang F, Chiravuri S. Recurrent cellulitis associated with long-term intrathecal opioid infusion therapy: a case report and review of the literature. Pain Med. 2010;11:972-976.
75. Huidobro-Toro JP, Huidobro F. Central effects of morphine, levorphanol, (-)-methadone and the opioid-like peptides beta-endorphin and D-alanine2- methionine enkephalinamide on urine volume outflow and electrolytes. J Pharmacol Exp Ther. 1981;217:579-585.
76. Danesh S, Walker LA. Effects of central administration of morphine on renal function in conscious rats. J Pharmacol Exp Ther. 1988;244:640-645.
77. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98-132.
78. Cridland RA, Henry JL. Intrathecal administration of substance P in the rat: spinal transection or morphine blocks the behavioural responses but not the facilitation of the tail flick reflex. Neurosci Lett. 1988;84:203-208.
79. Gold MS, Pottash AC, Sweeney DR, Kleber HD. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA. 1980;243:343-346.
80. Gold MS, Pottash AL, Sweeney DR, Davies RK, Kleber HD. Clonidine decreases opiate withdrawal-related anxiety: possible opiate noradrenergic interaction in anxiety and panic. Subst Alcohol Actions Misuse. 1980;1:239-246.
81. Kleber HD, Gold MS, Riordan CE. The use of clonidine in detoxification from opiates. Bull Narc. 1980;32:1-10.
82. Gold MS, Redmond DE Jr, Kleber HD. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry. 1979;136:100-102.
83. Chieng B, Keay KA, Christie MJ. Increased fos-like immunoreactivity in the periaqueductal gray of anaesthetised rats during opiate withdrawal. Neurosci Lett. 1995;183:79-82.
84. Christie MJ, Williams JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal?Trends Pharmacol Sci. 1997;18:134-140.
85. Radke AK, Rothwell PE, Gewirtz JC. An anatomical basis for opponent process mechanisms of opiate withdrawal. J Neurosci. 2011;31:7533-7539.
86. Taylor KM, Mark GP, Hoebel BG. Conditioned taste aversion from neostigmine or methyl-naloxonium in the nucleus accumbens. Physiol Behav. 2011;104:82-86.
87. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981;21:152-156.
88. Wolff K, Rostami-Hodjegan A, Shires S, et al.The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol. 1997;44:325-334.
89. Rohde DS, McKay WR, Chang DS, Abbadie C, Basbaum AI. The contribution of supraspinal, peripheral and intrinsic spinal circuits to the pattern and magnitude of Fos-like immunoreactivity in the lumbar spinal cord of the rat withdrawing from morphine. Neuroscience. 1997;80:599-612.
90. Rohde DS, Detweiler DJ, Basbaum AI. Spinal cord mechanisms of opioid tolerance and dependence: fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal [corrected]. Neuroscience. 1996;72:233-242.
91. Fleisher LA, Beckman JA, Brown KA, et al.ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;116:e418-e499.